Table 3. Results of network meta-analysis.
| a. Hazard ratios(HR) with 95% confidence interval (CI) for progression-free survival (PFS) | ||||||
| Osimertinib | ||||||
| 0.75(0.28–2.0) | F-TKIs+CT | |||||
| 0.74(0.25–2.3) | 0.99(0.45–2.2) | F-TKIs+Bev | ||||
| 0.60(0.22–1.6) | 0.80(0.43–1.5) | 0.80(0.36–1.8) | S-TKIs | |||
| 0.46(0.23–0.93) | 0.62(0.39–0.98) | 0.62(0.32–1.2) | 0.77(0.48–1.2) | F-TKIs | ||
| 0.34(0.09–1.3) | 0.45(0.15–1.4) | 0.46(0.13–1.5) | 0.57(0.18–1.7) | 0.73(0.26–2.0) | F-TKIs+Lin | |
| 0.20(0.10–0.43) | 0.27(0.18–0.41) | 0.27(0.15–0.50) | 0.34(0.23–0.50) | 0.44(0.35–0.56) | 0.61(0.24–1.52) | CT |
| b. Hazard ratios(HR) with 95% confidence interval (CI) for overall survival(OS) | ||||||
| Osimertinib | ||||||
| 0.87(0.56–1.3) | F-TKIs+CT | |||||
| 0.78(0.43–1.4) | 0.90(0.54–1.5) | F-TKIs+Bev | ||||
| 0.76(0.50–1.1) | 0.87(0.66–1.2) | 0.97(0.60–1.6) | S-TKIs | |||
| 0.63(0.43–0.91) | 0.73(0.57–0.92) | 0.81(0.51–1.3) | 0.83(0.70–0.99) | F-TKIs | ||
| 0.82(0.25–2.8) | 0.95(0.29–3.1) | 1.1(0.31–3.7) | 1.1(0.34–3.5) | 1.3(0.42–4.2) | F-TKIs+Lin | |
| 0.65(0.46–0.93) | 0.76(0.61–0.95) | 0.84(0.54–1.31) | 0.87(0.75–1.01) | 1.04(0.93–1.17) | 0.80(0.25–2.58) | CT |
| c. Odds ratios (OR) with 95% confidence interval (CI) for serious adverse events (SAEs) | ||||||
| Osimertinib | ||||||
| 0.18(0.06–0.56) | F-TKIs+CT | |||||
| 0.18(0.06–0.58) | 1.01(0.36–2.82) | F-TKIs+Bev | ||||
| 0.30(0.11–0.81) | 1.62(0.69–3.84) | 1.61(0.65–3.97) | S-TKIs | |||
| 0.67(0.28–1.61) | 3.68(1.83–7.41) | 3.65(1.72–7.74) | 2.27(1.38–3.73) | F-TKIs | ||
| 0.19(0.04–0.85) | 1.03(0.25–4.23) | 1.03(0.24–4.31) | 0.64(0.17–2.39) | 0.28(0.08–0.95) | F-TKIs+Lin | |
| 0.20(0.08–0.52) | 1.10(0.49–2.43) | 1.09(0.47–2.52) | 0.67(0.41–1.11) | 0.30(0.20–0.43) | 1.06(0.29–3.82) | CT |
Abbreviations: For survival outcomes (OS, PFS), an HR below 1 favors the column-defining treatment. For safety (SAEs), an OR below 1 favors the column-defining treatment. Comparisons with differences of statistical significance (p<0.05) are highlighted in bold format. TKIs, tyrosine kinase inhibitor; F, first-generation; S, second-generation; Bev, bevacizumab; CT, chemotherapy; Lin, Linsitinib.